Synthesis of novel purpurealidin analogs and evaluation of their effect on the cancer-relevant potassium channel KV10.1

PLoS One. 2017 Dec 8;12(12):e0188811. doi: 10.1371/journal.pone.0188811. eCollection 2017.

Abstract

In the search for novel anticancer drugs, the potassium channel KV10.1 has emerged as an interesting cancer target. Here, we report a new group of KV10.1 inhibitors, namely the purpurealidin analogs. These alkaloids are produced by the Verongida sponges and are known for their wide variety of bioactivities. In this study, we describe the synthesis and characterization of 27 purpurealidin analogs. Structurally, bromine substituents at the central phenyl ring and a methoxy group at the distal phenyl ring seem to enhance the activity on KV10.1. The mechanism of action of the most potent analog 5 was investigated. A shift of the activation curve to more negative potentials and an apparent inactivation was observed. Since KV10.1 inhibitors can be interesting anticancer drug lead compounds, the effect of 5 was evaluated on cancerous and non-cancerous cell lines. Compound 5 showed to be cytotoxic and appeared to induce apoptosis in all the evaluated cell lines.

MeSH terms

  • 3T3 Cells
  • 4-Butyrolactone / analogs & derivatives*
  • 4-Butyrolactone / chemical synthesis
  • 4-Butyrolactone / pharmacology
  • Animals
  • Apoptosis / drug effects
  • Cell Line, Tumor
  • Dose-Response Relationship, Drug
  • Drug Screening Assays, Antitumor
  • Ether-A-Go-Go Potassium Channels / antagonists & inhibitors*
  • HEK293 Cells
  • Humans
  • Mice
  • Neoplasms / pathology*
  • Potassium Channel Blockers / pharmacology*

Substances

  • Ether-A-Go-Go Potassium Channels
  • KCNH1 protein, human
  • Potassium Channel Blockers
  • 4-Butyrolactone

Grants and funding

The project MAREX, Exploring Marine Resources for Bioactive Compounds: From Discovery to Sustainable Production and Industrial Applications 2010-2014, was funded by the European Union Seventh Framework Programme grant no. FP7-KBBE-2009-3-245137 and is sincerely acknowledged (http://cordis.europa.eu/project/rcn/95006_en.html). LM is a recipient of a fellowship from the Agency for Innovation by Science and Technology in Flanders (IWT - 131231) (https://www.iwt.be/english/welcome). FZ was funded by Marie Curie Initial Training Network IonTraC (Grant # 289648) (https://campus.uni-muenster.de/iontrac/home/). PK and JY-K thank Academy of Finland for the project No. 285103 (http://www.aka.fi/en). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.